Generic Name and Formulations:
Brivaracetam 10mg, 25mg, 50mg, 75mg, 100mg; tabs.
Indications for BRIVIACT:
Partial-onset seizures, as monotherapy or adjunctive treatment in patients ≥4yrs.
Interchangeable with other forms. Tabs: swallow whole with liquid. Oral soln: use calibrated measuring device. May also give via nasogastric or gastrostomy tube. ≥16yrs: initially 50mg twice daily; may adjust down to 25mg twice daily or up to 100mg twice daily based on response and tolerability. Hepatic impairment: initially 25mg twice daily; max 75mg twice daily. Concomitant rifampin: double brivaracetam dosage.
<4yrs: not established. Interchangeable with other forms. Tabs: swallow whole with liquid. Oral soln: use calibrated measuring device. May also give via nasogastric or gastrostomy tube. 4–<16yrs (11–<20kg): initially 0.5–1.25mg/kg twice daily; may adjust down to 0.5mg/kg twice daily or up to 2.5mg/kg twice daily based on response and tolerability; (20–<50kg): initially 0.5–1mg/kg twice daily; may adjust down to 0.5mg/kg twice daily or up to 2mg/kg twice daily; (≥50kg): initially 25–50mg twice daily; may adjust down to 25mg twice daily or up to 100mg twice daily. Hepatic impairment (11–<50kg): initially 0.5mg/kg twice daily; max 2mg/kg twice daily (11–<20kg) or 1.5mg/kg twice daily (20–<50kg); (≥50kg): as Adult. Concomitant rifampin: double brivaracetam dosage.
Increased risk of suicidal behavior or ideation; monitor for clinical worsening and/or any unusual changes. Monitor for neurological and psychiatric adverse reactions. Discontinue if hypersensitivity reactions occur. Hepatic impairment: adjust dose (see Adult). End-stage renal disease undergoing dialysis: not recommended. Avoid abrupt cessation. Pregnancy. Nursing mothers.
Antagonized by rifampin (see Adult). Concomitant carbamazepine: may consider dose reduction if intolerant. May potentiate phenytoin; monitor phenytoin levels when adding or discontinuing brivaracetam from ongoing therapy. Concomitant levetiracetam: no added benefit.
Somnolence/sedation, dizziness, fatigue, nausea/vomiting; hematologic abnormalities.
To enroll in the North American Antiepileptic Drug Pregnancy Registry call (888) 233-2334.
Tabs—60; Oral soln—300mL; Single-dose vials—10
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally